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Periapical periodontitis results from pulpal infection leading to pulpal necrosis and
resorption of periapical bone. The current treatment is root canal therapy, which attempts
to eliminate infection and necrotic tissue. But, in some cases periapical inflammation
doesn’t resolve even after treatment. Resolvins belongs to a large family of specialized
pro-resolving lipid mediators that actively resolves inflammation signaling via specific
receptors. Resolvin D2 (RvD2), a metabolite of docosahexaenoic acid (DHA), was tested
as an intracanal medicament in rats in vivo. Mechanism was evaluated in rat primary
dental pulp cells (DPCs) in vitro. The results demonstrate that RvD2 reduces inflammatory
cell infiltrate, periapical lesion size, and fosters pulp like tissue regeneration and healing
of periapical lesion. RvD2 enhanced expression of its receptor, GPR18, dentin matrix
acidic phosphoprotein 1 (DMP1) and mineralization in vivo and in vitro. Moreover, RvD2
induces phosphorylation of Stat3 transcription factor in dental pulp cells. We conclude
that intracanal treatment with RvD2 resolves inflammation and promoting calcification
around root apex and healing of periapical bone lesions. The data suggest that RvD2
induces active resolution of inflammation with pulp-like tissue regeneration after root
canal infection and thus maybe suitable for treating periapical lesions.
Keywords: resolvin D2, resolution of periapical inflammation, periapical periodontitis, periapical lesion, DMP1,
calcification
INTRODUCTION
Periapical periodontitis is an inflammatory disease that occurs around the tooth root apex. It is
caused by infection of the dental pulp tissue subsequent to carious lesions and leads to resorption of
root dentin and bone (1). It is believed that presence of microorganisms in the root canal system are
associated with the development and progression of periapical periodontitis (2, 3). Conventional
root canal treatment goals to eliminate bacteria from the root canal system as completely
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as possible by physically removing the pulp soft tissue and
irrigating the root canal system with potent antiseptic solutions
(e.g., sodium hypochlorite), as well as mechanically removing
infected dentin in the root canal (4). The disinfected root
canals are then filled with an inert material, typically gutta
percha, to obturate the endodontic space to prevent bacterial
recolonization. The overall success rates for primary endodontic,
secondary endodontics, and surgical treatment reported by
Elimam et al. were 86.02, 78.2, and 63.4%, respectively, based
on criteria of the retention of a functional tooth over a 4 years
period. (5). Most failures occur because of ineﬀective microbial
clearance, which leads to continued periapical inflammation (6,
7). Root canal therapy also desiccates the tooth leading to the
potential for subsequent fracture. Considering the course which
pulpal inflammation initiates tissue destruction, it is obvious that
an important step in supporting the regeneration of pulp-like
tissue is the attenuation of inflammation.
Regeneration of pulp tissue after infection is limited, and
attempts have repeatedly failed, because current methods cannot
control inflammation and eliminate the bacterial infection (8).
The primary goal in regenerative procedure is to eliminate
clinical symptoms and resolve apical periodontitis as defined
by the American Association of Endodontists in Clinical
Considerations for a Regenerative Procedure (9). Thickening
of canal walls and constant root maturation characterized by
continued odontoblast activity, which produces calcified tissues,
is the secondary goal. Currently, non-surgical root canal therapy
replaces infected vital and necrotic tissue with biocompatible
foreign materials in disinfected root canals. The goal of
regenerative therapy is to fill formerly infected canals with the
host’s own vital tissue (9). Earlier, it was believed that successful
regeneration cannot be achieved once tooth has become infected.
However, recent studies suggest that regenerative endodontics
may in fact be possible in teeth with pulpal necrosis and
periapical pathology. Maintaining patency of the root apex
opening is thought to be a critical component for regeneration as
multiple studies in experimental animal models have revealed the
regeneration of dental pulp-like tissue after evoked bleeding by
instrumentation (10, 11).
Dental pulp cells (DPCs) are progenitor cells with the ability
for self-renewal and multilineage diﬀerentiation. In response
to trauma or injury, DPCs diﬀerentiate into odontoblast-
like cells and initiate dentin mineralization by expressing
extracellular acidic proteins that participate in dentin repair and
mineralization (12). Dentin matrix protein-1 (DMP1) plays a
key role in odontoblast diﬀerentiation, formation of the dentin
tubular system, and mineralization. DMP1 is expressed by both
pulp progenitor cells and odontoblasts and its deletion leads
to defects in odontogenesis and mineralization (13). It has
been suggested that DPCs can be transplanted or expanded in
a sterile root canal to diﬀerentiate and induce mineralization
and promote periapical healing (12, 14). The clinical limitation
to this approach is the diﬃculty in controlling infection
and inflammation.
Resolvins belongs to a family of lipidmediators biosynthesized
from omega-3 polyunsaturated fatty acids (eicosapentaenoic
acid, EPA and docosahexaenoic acid, DHA) that promote the
resolution phase of inflammation. In periodontitis and other
infectious/inflammatory diseases, resolvins promote clearance of
bacteria, and tissue regeneration (15, 16). The lipid mediator
resolvin D2 (RvD2) promotes bacterial clearance and improves
animal survival in a cecal ligation and puncture model of
sepsis (16). RvD2 is defensive against P. gingivalis provoked
periodontal bone loss and has been shown to regulate the
RANKL/OPG ratio (17). RvD2 enhances post-ischemic limb
revascularization during ischemia by promoting arteriogenesis
(18), controlling bacterial sepsis and resolving inflammation
by promoting polymorphonuclear neutrophil (PMN) apoptosis,
and enhancing macrophage eﬀerocytosis (16, 19). RvD2 is also
known to reduce postoperative pain by inhibiting transient
receptor potential channels in sensory neurons (20). Considering
the demonstrated regeneration of periodontal tissues with
resolvin treatment and the demonstrated actions of RvD2 in
a variety of infectious / inflammatory disease systems, it is
reasonable to expect that the active proresolving actions of
RvD2 and its demonstrated enhancement of bacterial clearance
will be beneficial in healing of periapical lesions. We examined
whether RvD2 can be used as an intracanal medication to
promote periapical healing and investigated potential mechanism
of action.
MATERIALS AND METHODS
Animals
Eighteen 10-week old maleWistar rats (CLEA Japan, Inc., Tokyo,
Japan) were maintained in the animal facility of Department of
Animal Resources, Advanced Science Research Center, Okayama
University with a 12-h light/12-h dark cycle. Food and water were
provided ad libitum.
Induction of Periapical Periodontitis
The experimental design is shown in Figure 1. Rats were
administered general anesthesia by intraperitoneal injection of
sodium pentobarbital (50 mg/kg IP). After 15–20min to ensure
complete anesthesia, all surgical procedures were performed
under a microscope (Nikon Smz-645, Tokyo, Japan). Periapical
lesions were induced by exposing the pulp of the mandibular
right and left first molars using a #1/2 8ISO 006 round
bur (Dentsply Maillefer, Ballaigues, Switzerland) in an electric
handpiece (VIVAMATE G5; NSK, Tochigi, Japan). The exposed
pulps were left open to the oral environment for 3 weeks to
ensure bacterial contamination. Opposing maxillary first molars
in contact with the experimental teeth were removed at the same
time as pulp exposure of the mandibular first molars to prevent
tooth fracture (1).
After 3 weeks, the right and left mandibular first molars
were endodontically treated by cleaning the test tooth with
70% ethanol. A #1/2 round bur was used to open the pulp
chamber and remove the necrotic coronal pulp, and a micro-
excavator (OK Micro-exca; Seto, Ibaraki, Japan) was used to
remove the infected tooth substance from the pulpal floor
and the orifice of the root canals. K-files #6–20 (Dentsply
Maillefer) were placed up to 2.5mm in depth into the mesial
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FIGURE 1 | Experimental protocol of rat periapical periodontitis model. (A) Root canal treatment was performed 3 weeks after pulp exposure and rats were sacrificed
and evaluated 4 weeks after treatment. (B) Cavity preparations of first molar, root canal treatment, and final restoration under microscope guidance.
and distal root canals to mechanically debride the root canals,
followed by irrigation with 0.5mL of 2.5% sodium hypochlorite
(Neo Dental Chemical Products, Tokyo, Japan) using 30-gauge
needles (NaviTip, Ultradent Products, Tokyo, Japan) at a flow
rate of 1 mL/min (1). In order to facilitate bleeding from
periapical lesion into the canals, we breached the apical foramen
using # 20K file. Treated canals were dried using sterilized
paper points (VDW, Munich, Germany) and filled with 20
µL RvD2 (1µg/mL, Cayman Chemical, Ann Arbor, MI, USA)
delivered with a mixture of propylene glycol (Nacalai Tesque)
and Macrogol (Meiji Yakuhin, Toyama, Japan) as a carrier
with 30-gauge needles (21, 22). K file #15 was used in a
clockwise motion to facilitate RvD2 delivery inside the canal
and beyond the apex, until RvD2 changed from colorless to
reddish color due to blood. This was followed by drying of
the coronal chamber using sterile cotton. Untreated mandibular
molars, sealed only (SO group; same treatment without any
administration) and with vehicle only (VO group; a mixture
of propylene glycol and Macrogol) served as controls. Finally,
pulp chambers were lined with apatite liner (Dentsply-Sirona,
Tokyo, Japan) followed by filling with flowable composite resin
(MI FLOW, GC, Tokyo, Japan). In this study. 13 rats were used
for the test with control group (Group #1); RvD2 (right side)
and SO (left side) sides for each rat. On the other hand, 3 rats
were used for control only group (VO group; Group #2). Two
rats were used for the baseline group; Group #3. For in vivo
imaging analysis, 3 rats used were from Group #1. For micro-CT
analysis, 4 rats were used from Group #1. For histology, Gram
staining, and immunohistochemistry, 5 rats were used from
group #1, 3 from Group #2, and 2 from Group #3. In addition,
for q-PCR analysis for bacteria (Figure S3), 1 rat was used
from Group #1.
In vivo Imaging
After 4 weeks of treatment, in vivo imaging was performed
to measure myeloperoxidase (MPO) activity of activated
phagocytes. Dose of XenoLight RediJect inflammation probe
(PerkinElmer, Waltham, MA) was calculated and administered
intraperitoneally at 150 µL/30-g weight, and sacrificed
immediately. To eliminate errors in measurement due to
positional eﬀects of the specimen, the dissected mandibles were
trimmed to the same size and thickness. After verifying that the
wavelengths from specimens positioned on a plate and from the
emission filters of the device were almost the same across all
samples, luminescent images were taken using a charge-coupled-
device (CCD) camera within 20min of injection. Luminescence
intensity was measured using IVIS Spectrum (PerkinElmer),
and a circular region of interest (ROI) was defined as a region
which exhibited more than 50% of maximum luminescence
in the inflammatory site of each rat. The total flux (measured
in photons per second) in the ROI were quantified using
Living Image Software V4.4 (PerkinElmer) according to the
manufacturer’s instructions (23).
Micro-CT Analysis
Periapical lesions were scanned with a µCT scanner
(SkyScan1174v2; Bruker-µCT, Billerica, MA, USA) 4
weeks after treatment. After scanning, the image data were
reconstructed using the Nrecon system (Nrecon Bruker-µCT).
For visualization, samples were digitally reconstructed so that a
two-dimensional slice showing a patent mesial and distal canal
in the first molar could be obtained. Periapical lesion sizes in
the cross sectional area from the apical third of the canals were
measured using ImageJ software (NIH, Bethesda, MD, USA),
and values in square millimeters were compared between the
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RvD2 and control groups (24). To obtain the precise periapical
lesion size, the periodontal ligament space around the apical
third of the mesial and distal root canals in healthy teeth were
measured, and their values were subtracted from the periapical
lesion size values of the RvD2 and control groups.
Histology
Rats were sacrificed 4 weeks after treatment. Mandibular
samples containing the first molars were dissected, fixed in 4%
paraformaldehyde, and decalcified in 10% formic acid for 10
days at room temperature. After preparation of 4-µm serial
sections, some sections were stained with hematoxylin and eosin
(HE) to observe cellular composition, while others were stained
using a modified Brown and Brenn method (25), to observe
microorganisms (Gram-positive or Gram-negative) under a
DP70 light microscope (Olympus, Tokyo, Japan).
Immunohistochemistry
Immunohistochemistry was performed using a streptavidin-
biotin complex method. Rabbit anti-GPR18 polyclonal antibody
(Abcam, Cambridge, UK) at a 1:100 dilution and rabbit anti-
DMP1 polyclonal antibody (Takara Bio, Shiga, Japan) at 1:200
dilutions were used as primary antibodies as previously described
(26). Secondary antibodies were goat anti-rabbit conjugated
with biotin antibody (Vectastain ABC kit; Vector Laboratories,
Burlingame, CA, USA) at 1:200 dilution. Immunoreactivity was
visualized using the DAB Substrate Kit (Vector Laboratories)
and counterstained with Mayer’s hematoxylin solution. Negative
control staining was performed in parallel by incubating the
sections with phosphate-buﬀered saline (PBS) rather than with
primary antibody.
DPC Isolation and Culture
After sacrifice, the incisors from animals were carefully separated
from the jawbones. Dental pulps were gently isolated using a
sterile dental explorer and the apical third of the tooth was cut
oﬀ to obtain the apical epithelial buds as previously described
(27). The remaining pulp tissue was minced into small pieces
and treated with solution containing 3 mg/mL collagenase type
1 (Sigma-Aldrich, St. Louis, MO, USA) and 4 mg/mL dispase
(Sigma-Aldrich) for 60min at 37◦C. The single-cell suspension
was cultured in alpha minimum essential medium (α-MEM;
Gibco, Life Technologies, Grand Island, NY, USA) supplemented
with 20% fetal bovine serum (Hyclone, Logan, UT, USA),
1% 100 U/mL penicillin, 100µg/mL streptomycin, 0.25µg/mL
amphotericin B, and 1% L-glutamine at 37◦C in 5% CO2. The
cells were routinely observed under a TS100-F phase-contrast
inverted microscope (Nikon, Tokyo, Japan). Cells at passage four
were used in subsequent experiments. To treat DPCs with RvD2,
osteogenic medium containing 200µM ascorbic acid, 10mM,
ß-glycerophosphate, and 100 nM dexamethasone was prepared.
Alizarin Red S Staining
Cells were cultured on 48-well plates, and the five diﬀerent
groups (0, 1, 10, 100, and 200 nM) were established. Media
with and without RvD2 were replaced twice per week with
freshly-prepared osteogenic media. On day 21, cells were fixed
TABLE 1 | Primers used in the study.
GPR18
Forward AAATGATCACCCTGAACAATCAAGA
Reverse ATTCATAACATTTCACTGTTTATATTGCTTAG
DMP1
Forward ACCTTTGGAGACGAAGACAATGGC
Reverse ACACCACACAGTCCAGTGAAGACA
BETA ACTIN
Forward TGTTGCCCTAGACTTCGAGCA
Reverse GGACCCAGGAAGGAAGGCT
with phosphate-buﬀered formalin and then stained with 250
µL alizarin red, ARD-A1 (ARD-SET, PG Research, Tokyo,
Japan) for 30min. After washing the wells with pure water,
the plates were photographed. After staining, quantitative
analysis of mineralization was carried out using 250 µL
ARD-E1 (ARD-SET, PG Research, Tokyo, Japan) and plates
were stirred for 10min to elute the dye, and then 100 µL of
solution was transferred into 96-well plates and absorbance
measurement was recorded at 450 nm using microplate
reader (iMark
TM
Microplate Absorbance Reader, Bio-Rad,
Hercules, CA, USA) (28).
Real-Time Reverse Transcription
Polymerase Chain Reaction (Real-Time
RT-PCR)
DPCs were cultured in 12-well plates until 80% confluence,
treated with 0–100 nM doses of RvD2, and incubated at
37◦C for 7 and 14 days. Every 72 h, the media containing
RvD2 doses were changed. For real-time RT-PCR, the cells
were lysed to extract total RNA using the RNeasy Mini Kit
(Qiagen GmbH, Hilden, Germany). Concentrations of mRNA
were measured spectrophotometrically using a NanoDrop 2000
spectrophotometer (Thermo Fisher Scientific, Waltham, MA,
USA). One microgram of each RNA sample was subjected to RT
using the SuperScript IV VILO cDNA synthesis kit (Invitrogen,
Carlsbad, CA, USA). Quantitative RT-PCR was performed using
an ABI 7300 system (Applied Biosystems, Foster City, CA) under
conditions of 95◦C for 10min followed by 40 cycles at 95◦C
for 15 s and 60◦C for 1min in 96-well plates in a final volume
of 20 µL containing SYBR green PCR master mix (Applied
Biosystems) (23). The primers used for detection are listed in
Table 1. Measured mRNA levels were normalized to the mRNA
copies of β-actin. We performed these experiments using three
diﬀerent cell samples and quantification of mRNAwas confirmed
using the same cell sample in triplicate.
Western Blot Analysis
Western blotting was performed as described previously (29).
DPCs were treated with or without RvD2 (1–100 nM) for
14 days, washed with cold PBS twice, lysed using cell lysis
buﬀer containing 50mM sodium chloride, 10mM, Tris-HCl (pH
7.2), 1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40, and
5mM sodium ethylenediamine tetraacetate, and collected in a
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1-mL centrifuge tube. After centrifugation of the cell lysate,
supernatants containing total protein were transferred to new
tubes, and protein concentration was determined with the BCA
protein assay (Thermo Fisher Scientific). Thirty micrograms of
each sample were subjected to 12% SDS-PAGE and transferred to
a polyvinylidene fluoridemembrane (Bio-Rad). Membranes were
incubated overnight at 4◦C with a polyclonal rabbit anti-DMP1
antibody (Takara Bio) at a dilution of 1:2,000. Subsequently,
the membrane was incubated with anti-rabbit IgG polyclonal
antibody (GE Healthcare Life Sciences, Little Chalfont, UK) at a
dilution of 1:2,000, and then washed with PBS containing Tween
(PBST) buﬀer to remove unbound antibody. The membrane was
developed with enhanced chemiluminescence detection reagents
(SuperSignalWest Pico; Thermo Fisher Scientific). Anti-GAPDH
antibody (Cell Signaling Technology, Danvers, MA, USA) was
used as an internal control at a dilution of 1:1,000). Each
experiment was performed in triplicate and data values were
normalized to the corresponding GAPDH values. Densitometric
analysis was performed using ImageJ software.
To determine the expression levels of pSTAT3 protein, only α-
MEM containing 100 nM RvD2 was used. Cells were treated with
α-MEMwith/without 100 nM RvD2 and incubated for 0, 1, 5, 15,
and 30min at 37◦C in 5% CO2, followed by washing with cold
PBS twice and lysis using cell lysis buﬀer. The lysate was added to
500-µL tubes that were transferred to ice to stop the reaction.
Protein concentration was determined with the BCA protein
assay and 10 µg of each sample was subjected to 12% SDS-
PAGE and transferred onto a polyvinylidene fluoride membrane,
followed by overnight incubation at 4◦C with a polyclonal
rabbit anti-pSTAT3 (Cell Signaling Technology) at a dilution of
1:1,000. Subsequently, the membrane was incubated with anti-
rabbit IgG polyclonal antibody (GE Healthcare Life Science) at
a dilution of 1:2,000, and then washed with PBST buﬀer to
remove unbound antibody. Anti-STAT3 antibody (Cell Signaling
Technology) was used as an internal control at a dilution of
1:1,000. Each experiment was performed in triplicate and data
values were normalized to the corresponding total STAT3 values.
Densitometric analysis was performed using ImageJ software.
Statistical Analyses
For in vivo imaging and micro-CT analysis, Mann-Whitney
test was used to determine statistically significant changes in
the level of periapical inflammation and periapical lesion area
between the treatment and control groups. For Alizarin red
staining for mineralization, qPCR and Western blotting analysis
for DMP1 mRNA and protein expression, one-way ANOVA
and post hoc Tukey-Kramer test was used. For pSTAT3 analysis,
Mann-Whitney test was used to determine statistically significant
diﬀerence between RvD2 and control groups. In all cases, P <
0.05 was considered statistically significant (∗).
RESULTS
RvD2 Reduced MPO Activity in Periapical
Periodontitis
Molecular imaging analysis was performed to measure
myeloperoxidase (MPO) activity to examine the
FIGURE 2 | Molecular imaging analysis examining the effects of RvD2 on
periapical inflammation. Images of the signal intensity of MPO activity around
RvD2 treated and non-treated tooth are shown (A). Results of comparisons of
the levels of signal intensity with respect to total flux are shown (B). Data
represent the means of three independent rats (SO on left side and RvD2 on
right side for each rat), with error bars indicating standard deviations. *P <
0.05 indicates significant differences compared to the control group,
Mann–Whitney test.
anti-inflammatory eﬀects of the RvD2. Data revealed that
level of periapical inflammation was significantly reduced in
RvD2-treated molars. In the SO group, periapical inflammation
was higher (Figure 2A). The average level of total flux was in
RvD2 treated teeth was 42.34% ± 16.78 and for control samples
set value in percentage was 100%± 0 (∗P < 0.05, Figure 2B).
RvD2 Reduced Periapical Lesion Size
Infected root canals were cleaned and sealed after administration
of RvD2. Micro-computed tomography (µCT) analysis was used
to quantify the area of mineralized tissue and showed that the
periapical lesion size was greatly reduced, and root canal apices
were calcified in RvD2-treated molars. In the SO group, root
apices were open with large periapical lesions (Figure 3A). The
mean periapical lesion size in RvD2 treated teeth (apex of mesial
canal) was 0.149± 0.146mm2, and non-treated teeth was 0.391±
0.119mm2. Themean periapical lesion size in RvD2 treated distal
canals was 0.059± 0.103 mm2, and non-treated distal canals was
measured 0.292± 0.082 mm2 (∗P < 0.05, Figures 3B,C).
Histology
Histological examination of samples revealed that RvD2
induced root apex closure and reduced inflammatory cell
accumulation in periapical tissues (Figures 4A,E). The control
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FIGURE 3 | Micro-CT analysis of periapical lesions after root canal treatment in rats. (A) Representative image of teeth in the treatment group and SO group. The
x-axis (white line) passes through the apical third of the mesial and distal root canal, denoted as the coronal limit of periapical lesion. The y-axis (green line) passes
through the center of the mesial and distal root canals of the mandibular first molars. (B,C) Comparison of changes in the size of periapical lesions in mesial and distal
canals (*P < 0.05 indicates significant differences compared to the SO group, Mann–Whitney test). Data represent the means of four independent rats (SO on left side
and RvD2 on right side for each rat), with error bars indicating standard deviations. The volume of the periapical lesions of the mesial and distal roots for the treatment
group were significantly lower than that of the control group after 4 weeks following pulp exposure.
FIGURE 4 | Histological analysis of periapical lesions after root canal treatment in rats. (A) Periapical area of treatment group stained with HE. (B,C) Periapical area of
control groups stained with HE. (D) Periapical area of baseline group stained with HE. (E,F,G,H). High magnification views of the solid inset in (A–D), respectively.
(I–L). High magnification views of the solid insets in (A–D), stained with a modified Brown and Brenn method. Images are representative for 5 experiments from Group
#1 (RvD2 and SO); 3 experiments from Group #2 (VO), and 2 experiments Group #3 (baseline). RC, root canal; CA, closed apex; OA, open apex; AF, apical foramen.
The asterisk denotes inflammatory cells and the black arrows specifying some of Gram negative bacteria stain red color and blue arrow specifying some of blue/purple
stain Gram positive bacterial cells in canals. Outlined circular images with blue and black colors are higher magnification of specified areas coming from colored dotted
circles corresponds to the identifications of Gram positive and negative bacteria.
groups SO and VO did not exhibit root apex closure, and the
periapical lesion contained inflammatory granulation tissue with
marked inflammatory cell infiltration and numerous PMNs,
lymphocytes, and monocytes (Figures 4B,C,F,G). Baseline
data (0 week) shows development of periapical periodontitis
(Figures 4D,H). Modified Brown and Brenn staining revealed
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FIGURE 5 | Immunohistochemical analysis. (A) GPR18 protein expression in the root canal of the treatment group. (B,C) GPR18 protein expression in the root canal
of the control groups. (D–F) High magnification views of the solid inset in the panels (A–C), respectively. (G) DMP1 protein was abundantly expressed in the root
canals of the treatment group. (H,I) Whereas, DMP1 protein expression was lower in the root canal of the control groups as compared to RvD2 group. (J–L) High
magnification views of the solid inset in the panels (G–I), respectively. Images are representative for 5 experiments from Group #1 and 3 experiments from Group #2.
(M) Negative control without primary antibody GPR18. (N) Negative control without primary antibody DMP1. RC, root canal; C, cementum. The arrow head indicates
GPR18 and DMP1 positive expression.
few residual bacteria in RvD2-treated canals compared to the
abundant bacteria in control root canals (Figures 4I–L).
Immunohistochemical Detection of GPR18
and DMP1 in Root Canal Tissues
Immunohistochemistry revealed strong GPR18 protein
expression inside and around the root canals in the RvD2-
treated group compared to the controls SO, and VO, suggesting
the upregulation of the receptor by RvD2 treatment. Expressions
were observed inside root canals and in the periodontal ligament
space region (Figures 5A–F). DMP1, a key phosphoprotein
for dentin mineralization and odontoblast diﬀerentiation, was
highly expressed in RvD2-treated root canals scattered near the
root dentin and mid-root and in the apical region (Figures 5G,J).
In the control groups, SO and VO, DMP1 protein was expressed
only in the root dentin (Figures 5H–L). Negative controls,
without GPR18 and DMP1 antibodies (Figures 5M,N).
Alizarin Red Staining
After stimulation of DPCs with RvD2 in culture at doses
of 1–200 nM for 21 days, there were obvious diﬀerences in
the amounts of mineralization among the groups (Figure 6A).
Among treatment groups, 100 nM and 200 nM had significantly
increased amount of mineralized nodules as compared with
control (0 nM) (Figure 6B). Whereas, 1 and 10 nM doses showed
slight tendency to induce mineralization in DPCs.
Expression of DMP1 mRNA in DPCs
After stimulation of DPCs with RvD2 in culture at doses
of 1–100 nM for 7 and 14 days, quantitative real-time PCR
analysis revealed that DMP1 mRNA expression was significantly
enhanced at each dose at 7 days compared to that in the control (P
< 0.05, Figure 7A). After 14 days of culture, DMP1 mRNA was
significantly enhanced at 100 nM compared to that in the control
(P < 0.05, Figure 7B).
Expression of DMP1 and Phosphorylated
Signal Transducer and Activator of
Transcription 3 (STAT3) Protein in DPCs
Western blotting data confirmed that RvD2 induced DMP1
protein expression in DPCs stimulated with RvD2 for 7 and 14
days. After 7 days, RvD2 induced DMP1 protein expression at
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FIGURE 6 | Alizarin red staining of DPCs stimulated with and without RvD2
(1-200 nM) for 21 days. (A) Obvious differences in the amounts of
mineralization among the groups. (B) Quantitative analysis showed that 100
and 200 nM had significantly increased mineralized nodules as compared with
control 0 nM (P < 0.05; Tukey-Kramer). *P < 0.05 indicates significant
differences compared to the control, post hoc Tukey-Kramer test.
Representative data of four independent samples.
all doses of 1 to 100 nM (Figure 8A). Whereas, after 14 days
DMP1 protein expression was significantly enhanced at the doses
of 10 and 100 nM (P < 0.05, Figure 8B). Phosphorylated STAT3
protein expression was significantly induced after DPCs were
stimulated with 100 nM of RvD2 for 1min compared to that in
the control. Additionally, phosphorylation of STAT3 was notably
higher than that in non-treated DPCs after stimulation for 5 and
15min (P < 0.05, Figure 8C).
DISCUSSION
In this study, we demonstrate that active control of excess
inflammation in an infected root canal is permissive for the
healing of periapical lesions. In addition, there was suggestive of
successful vital pulp-like tissue regeneration and bacterial load
reduction in contaminated root canals following topical RvD2
treatment. Vital pulp-like tissue was regenerated with significant
increases in DMP1 expression and mineralization. RvD2 signals,
at least in part, through STAT3. The net outcome of RvD2-
augmented root canal therapy was continued calcification around
root apex, prevention and reversal of periapical periodontitis.
Resolvins are specialized pro-resolving mediators derived
from the polyunsaturated omega-3 fatty acids, EPA and DHA,
which yield E-Series resolvins and D series resolvins, respectively
(30). Resolvins actively foster catabasis through potent pro-
resolving and anti-inflammatory actions (31, 32). Specialized
pro-resolving mediators derived from DHA, including RvD2,
were first noticed and isolated during the resolution phase of self-
limited acute inflammation from murine self-resolving exudates
FIGURE 7 | Quantification of DMP-1 mRNA from DPCs stimulated with RvD2
(1–100 nM) for 7 and 14 days using real-time RT-PCR. (A) RvD2 induced
significant DMP1 mRNA expression at all doses after 7 days culture compared
to the control (0 nM) (P < 0.05; Tukey-Kramer). (B) RvD2 induced significant
DMP1 mRNA expression at 100 nM (P < 0.05; Tukey-Kramer) after 14 days
culture compared to the control (0 nM). *P < 0.05 indicates significant
differences compared to the control, post hoc Tukey-Kramer test.
Representative data of three to four independent cases.
(33). Resolvin D2 biosynthesis involves 17-lipoxygenation of
DHA to 17S-hydroperoxy-DHA, which then further transformed
enzymatically to a 7(8) epoxide-containing intermediate in
leukocytes via 5-lipoxygenase, followed by enzymatic hydrolysis
to form RvD2. Endogenous RvD2 production has been
documented in human serum, plasma, adipose tissue, placenta,
lung, breast milk, and in the plasma of sepsis patients. RvD2
is a potent immunoresolvent that stereoselectively reduces
excessive PMN traﬃcking in peritonitis and improves survival
in sepsis. It sharply decreased excessive cytokine production,
neutrophil recruitment, both local and systemic bacterial burden,
while increasing peritoneal mononuclear cells, macrophage
phagocytosis and intracellular generation of phagosomal reactive
oxygen species for microbial killing in the mice suﬀered
from microbial sepsis initiated by cecal ligation and puncture
(16). Moreover, RvD2 promote resolution by preventing the
generation of activated Th1 and Th17 cells and enhancing the
diﬀerentiation of regulatory T-cells (19). In addition, resolvins are
protective against P. gingivalis induced periodontal bone loss and
reverses periodontal bone loss by enhancing bacterial clearance
and regulating the RANKL/OPG ratio in murine periodontitis
model (17, 34). Overall, RvD2 is an eﬀective endogenous
controller of excessive inflammatory responses that actions on
multiple cellular targets to stimulate resolution, preserve and
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FIGURE 8 | Western blot analysis. (A) RvD2-induced DMP1 protein expression in 7 days DPC culture at all doses of 1 to 100 nM. (B). RvD2-induced DMP1 protein
expression in 14 days DPC culture. DMP1 expression was significantly enhanced at 10 and 100 nM doses compared to at 1 and 0 nM as the control groups (P <
0.05; Tukey-Kramer). Representative data of three independent cases. (C) RvD2 induced phosphorylation of STAT3 in DPCs. Cells were stimulated with RvD2
(100 nM) for 0, 1, 5, 15, and 30min. Western blotting revealed that RvD2 significantly induced phosphorylation of STAT3 after 1-min stimulation compared to
non-treated DPCs. In addition, phosphorylation of STAT3 was much higher than in non-treated DPCs after stimulation for 5 and 15min (*P < 0.05 indicates significant
differences compared to the control group, Mann–Whitney test). Representative data of three independent experiments. M, molecular weight marker.
improve immune vigilance (16, 35). Importantly, in many disease
systems, it has been shown that resolvins can be administered
in an active infectious/inflammatory lesion without negative
eﬀects. Bacteria are more eﬃciently cleared and there is no
increase of disease activity. The collective data indicate that for
all RvD2 actions, such as pro-resolution, anti-inflammation, and
the ability to promote bacterial clearance (16), RvD2 appears to
be suitable as an intracanal medication for endodontic treatment.
Periapical periodontitis is characterized by inflammation
and destruction of periapical tissues caused by etiological
bacteria of endodontic origin. It is considered to be the
consequence of a dynamic encounter between root canal
microbes and host defense. The latter involves cells, specifically
PMNs and macrophages, intercellular mediators, metabolites,
eﬀector molecules, and humoral antibodies (36). Principally,
macrophages play key role in clearance of bacteria, cellular
debris and apoptotic PMNs to facilitate inflammation-resolution
(16). If dying cells are not cleared, their intracellular contents
are expelled, creating an unfavorable environment that may be
favorable for bacteria to grow (37). In current clinical practice,
there are many materials that do not actively stimulate an
immune response such as gutta-percha used inside root canals
which has little bioactivity and few innate anti-inflammatory
properties. These materials lack active anti-inflammatory and
regenerative properties and significantly limits treatment options
favorable to reverse periapical periodontitis and to drive pulpal
regeneration (38).
Intracanal treatment with RvD2 reduced overall inflammation
by decreasing MPO activity of phagocytes as compared to
control (Figures 2A,B). We believe this change in MPO
activity is in accordance with the normal innate immune
response. Myeloperoxidase (MPO) activity has been used as an
inflammatory marker of both acute and chronic conditions. In
PMNs, amount of MPO is 3 times higher than in monocytes, and
used as an indicator of PMN presence in inflamed tissues (39). In
this study, we visualized in vivo monitoring of low MPO activity
in RvD2 treated tooth as compared to non-treated tooth. RvD2
limits excessive neutrophil traﬃcking to site of inflammation
and resolve inflammation whereas, unresolved inflammation and
tissue destruction are linked to dysregulated PMN functions (16).
Further, RvD2 reduced inflammatory cell infiltrates that could
be seen histologically (Figures 4A,E). Moreover, RvD2 induced
root apex closure and remarkably reduced periapical lesion size
with recalcification of bone at 4 weeks after root canal treatment
compared to the control group, where large periapical lesions
were observed (Figure 3; Figure S2).
In the present study, maintaining root apex patency was
considered an important step of the regeneration process, as
it has been previously reported by others that the periapical
tissues contain a higher concentration of stem cells compared
with the blood from the systemic circulation (40, 41). Thus, we
instrumented beyond the apex inducing bleeding inside canals.
Formation of blood clot creates a 3-D fibrin scaﬀold that may
contain stem cells derived from peripheral blood, periodontal
ligament, bone marrow, granulation tissue, or periapical lesions
(42). Further, it is likely that the presence of RvD2 restricts
excessive innate inflammatory responses in periapical lesions to
stimulate periapical repair (16, 17, 19).
Ten-week-old rats were used in this study, because their roots
are completely developed at this age. In older rats, it is diﬃcult
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to use files inside root canals due to continued calcification that
makes canals rigid and narrow (1). We measured the periapical
lesion size from the apical third of the root canal because
of the presence of accessory canals in this area (43). In rats,
induced periapical lesions develop rapidly between days 0 and
15 (active phase) and more slowly thereafter (chronic phase).
On days 15 to 90, lymphocytes are the predominant cell type
(50 to 60%) followed by polymorphonuclear leukocytes (25 to
40%), macrophage-monocytes, plasma cells, and blasts. The cell
infiltrate in these lesions was similar to that found in chronic
human periapical tissues (44).
Our histological findings are consistent with those of previous
studies, which used Resolvin E1 (RvE1) as an intracanal
medicament in necrotic immature pulps of teeth of 4-week-
old rats and demonstrated reductions in inflammatory cell
infiltration (22). Both resolvin types (E1 and D2) bind to
distinct cell receptors and elicit distinct responses. RvE1 binds
to chemokine-like receptor 1 (ChemR23) or BLT1 receptors on
monocyte, PMNs, osteoblasts, and osteoclasts (45). In addition
to the anti-inflammatory and pro-resolution actions mediated
by RvE1, osteoblasts mediate bone preservation via ChemR23
receptors (45). RvD2 binds to the GPR18 receptor, which is
expressed on human leukocytes, including PMNs, monocytes,
and macrophages, and elicits potent anti-inflammatory and
anti-bacterial responses (16, 35). In this study, we found high
expression of GPR18 receptors inside and outside of RvD2-
treated root canals as compared to the controls (Figures 5A–F),
which was further confirmed by the increased level of GPR18
mRNA expressed by DPCs treated with 10 nM RvD2 for 3 days
(Figure S1). These findings are consistent with previous reports
that demonstrate stem cells and macrophages express lipoxin
and resolvin receptors and respond to exogenous addition of
mediators (46, 47). The data expand our understanding of root
canal biology beyond the possible anti-inflammatory actions of
RvD2 on PMNs and macrophages located inside and outside the
root canal, revealing possible reasons for root apex calcification.
For regenerative endodontic therapy, the most commonly
used intracanal medication for canal disinfection and tissue
repair is triple antibiotic paste, which contains metronidazole,
ciprofloxacin, and minocycline (48). Local antibiotic medication
has many limitations, including the development of bacterial
resistance (49), allergic reactions (50), inhibition of angiogenesis
(51), and staining or discoloration of teeth (52). We used 2.5%
sodium hypochlorite for root canal irrigation, which has been
shown to have an essential role in reducing microbial load (48). It
has been studied that lipopolysaccharide (LPS/endotoxin) from
bacterial cell walls stimulates an inflammatory response from
a variety of cells resident in the tissue (53). Once immune
cells become activated by LPS, they mediate the destruction
of the pulpal tissues by secreting a range of pro-inflammatory
cytokines, prime examples being IL-1β and TNFα, and tissue
degrading enzymes such as matrix metalloproteinases (MMPs)
(54). Treatment with RvD2 may have further contributed to the
control of bacterial infection in the root canal by enhancing
phagocyte-dependent bacterial clearance (35). Very low levels
of residual bacteria were found in RvD2-treated root canals
as compared to control and baseline groups (Figures 4I–L).
Gram-negative bacteria predominate in root canals of teeth
with pulp necrosis and periapical lesions. LPS is considered
an important virulence factor of Gram negative bacteria (55).
Moreover, after 4 weeks of root canal treatment, we quantified
bacterial cells derived from the mesial root along with apical
region, using real-time PCR, as described by Maeda et al. (56).
We observed that bacterial cell counts were low in RvD2 treated
teeth as compared to control (SO) (Figures S3, S4).
There are many published case reports and series related
to the deposition of hard tissue within the canal walls of
teeth with necrotic pulps and apical lesions, elucidating the
obvious continuation of root development of teeth (57, 58).
Other multiple studies in experimental animal models have
shown the regeneration of dental pulp-like tissue after evoked
bleeding (10, 11), considering cells source from outside the
tooth root apex, likely including alveolar bone stem/progenitor
cells and periodontal ligament stem/progenitor cells (59).
Consequently, vital pulp-like tissue inside RvD2 treated canals
and calcified tissues around the root apex (Figures 4A, 5G)
presumably derived from alveolar bone stem/progenitor cells
and periodontal ligament stem/progenitor cells (60). Sustained
vitality of migrated pulp-like cells is likely because RvD2
treatment limits the excess local inflammatory response, controls
bacterial sepsis, stimulates stem cells and induces angiogenesis
(16, 18). Disease severity and chronicity involve a constant
phase of inflammation due to improper resolution of the
initial pro-inflammatory response that impacts on the resident
stem cells behavior (61), thus preventing tissue regeneration
while promoting pathogenesis of periapical lesion caused by
excessive influx of PMNs and pro-inflammatory mediators (6,
62). RvD2 actions, could promote resolution of inflammation
and reverse tissue destruction caused by excessive PMN influx
(16), consequently, facilitate stem cells activations presumably
alveolar bone stem/progenitor cells and periodontal ligament
stem/progenitor cells (46), and induce regeneration of pulp-like
cells and promote calcification of periapical lesion. In this rat
model, there was some slight ingrowth of pulp tissue in the
control, which is not often seen in humans. Nonetheless, the
robust ingrowth and large diﬀerence between RvD2 treatment
and control demonstrate significant impact of control of
inflammation in elimination of infection and promotion of
pulp regeneration.
In addition to the known actions of RvD2, it also induced
strong DMP1 expression throughout the root canal and around
the root apex including in cementum and bone. Moreover, in
vitro mineralization in primary DPCs was enhanced with RvD2
treatments at 100 and 200 nM doses at 21 days. (Figure 6). 21-
day DPC culture was chosen, since osteogenic diﬀerentiation
and mineralization is optimum at this time (63). We further
confirmed that DMP1 mRNA and protein levels were increased
in primary DPCs after treatment with RvD2 for 7 and 14
days (Figure 7, 8; Figures S5A,B). DMP1 mRNA expression
was significantly enhanced after 7 days treatment with RvD2
at all doses as compared to control (no RvD2). Whereas, at
14 days, the 100 nM dose showed a significant increase in
DMP1 expression. The diﬀerence in dose/response time could
be due to high cellular confluency in culture dishes incubated
for longer periods. It could be suggested that for the induction
of mineralization, persistent DMP1 expressions are needed. This
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time 10 to 100 nM dose induced DMP1 protein expression at
14 days (Figure 8B). We hypothesize that high concentration of
RvD2 is needed to keep DMP1 production and induce periapical
calcification. DMP1 is an extracellular acidic phosphoprotein
that belongs to the small integrin ligand N-linked glycoprotein
family 1, which has multiple functions in mineralized tissues.
It is also expressed in the cementum that coats the tooth root
surface (64). It plays a key role in odontoblast diﬀerentiation
and formation of the dentin tubular system. In response to pulp
injury, newly diﬀerentiated odontoblast-like cells from DPCs
play a role in dentin repair andmineralization by secreting DMP1
as a key protein that induces odontogenesis. Overexpression
of DMP1 by pluripotent cells acts as signal for diﬀerentiation
(14). In this case, diﬀerentiated odontoblast-like cells may have
shifted from the end of dentinal tubules toward the root apex
as dentin formation progressed (Figures 5G,J). Narrowing of the
root canal space was observed in some RvD2-treated molars,
likely in response to increased DMP1 protein. DMP1 is highly
acidic in nature and attracts calcium and promotes the nucleation
and growth of hydroxyapatite crystals (65). Localization of DMP1
in dentin and cementum is related to mineralization and its
deletion leads to increased susceptibility to periodontal diseases
in mice, suggesting that DMP1 is essential for the formation and
maintenance of a healthy periodontium (66, 67).
Finally, we identified a signaling pathway in DPCs involved
in the induction of DMP1 over-expression and odontoblast
diﬀerentiation. We observed that phosphorylation of STAT3
was enhanced after DPCs were treated with RvD2 (Figure 8C;
Figure S5C). The diﬀerences in STAT3 phosphorylation were
small; however, in normal cells, the duration of STAT3 activation
is short. Usually after exposure, phosphorylation takes peaks
within minutes (68). In our study, we found that DPCs expressed
phosphorylated STAT3 protein 1min after exposure. While
expression was also higher after 5 and 15min, we assume that
RvD2 activates STAT3 signaling in DPCs as early as in 1min
after exposure, and may persist until RvD2-receptor interactions
are saturated. STAT3 stimulates embryonic and somatic stem
cell self-renewal (69, 70). STAT3 also activates DPCs and
promotes their exit from the G0 phase of the cell cycle toward
self-renewal and diﬀerentiation (71). RvD2-GPR18 receptor
interactions on macrophage leads to the phosphorylation
of STAT3 that contributes in macrophage phagocytosis to
promote resolution of inflammation (35). Hence, in DPCs,
RvD2-GPR18 receptor interactions phosphorylates STAT3 to
further propagate DPC diﬀerentiation into odontoblast-like
cells. STAT3 is a positive regulator of β-catenin (72, 73), and
initiates DPC diﬀerentiation and upregulates DMP1 expression.
Further studies are needed to explore the signaling pathways
responsible for DPCs diﬀerentiation, DMP1 upregulation and the
mechanisms involving mineralization.
In conclusion, RvD2 eﬃciently reduces periapical
inflammation and promotes pulp-like tissue regeneration
and calcification around root apex. The positive healing response
could be associated with reduction of bacteria load. RvD2
enhances DMP1 expression by DPCs. RvD2 may be useful as a
novel intracanal medication for inducing pulpal regeneration in
endodontically compromised teeth.
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